MGC Pharmaceuticals Limited
MGCLF · OTC
12/30/2023 | 6/30/2023 | 12/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $3 | $2 |
| % Growth | -17.3% | -72.8% | 22.9% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $1 |
| Gross Profit | -$1 | -$0 | $1 | $1 |
| % Margin | -97.1% | -22.3% | 40.3% | 51.4% |
| R&D Expenses | $0 | $2 | $0 | $4 |
| G&A Expenses | $0 | $6 | $8 | $6 |
| SG&A Expenses | $6 | $7 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $1 | -$0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $6 | $7 | $7 | $9 |
| Operating Income | -$7 | -$7 | -$6 | -$8 |
| % Margin | -1,089.2% | -967.6% | -237.4% | -356.3% |
| Other Income/Exp. Net | -$1 | -$3 | -$5 | -$5 |
| Pre-Tax Income | -$7 | -$10 | -$11 | -$13 |
| Tax Expense | -$0 | $0 | $0 | -$0 |
| Net Income | -$7 | -$10 | -$11 | -$13 |
| % Margin | -1,180.2% | -1,371.3% | -408.6% | -596% |
| EPS | -0.003 | -3.27 | -3.8 | -4.73 |
| % Growth | 99.9% | 13.9% | 19.7% | – |
| EPS Diluted | -0.003 | -3.27 | -3.8 | -4.73 |
| Weighted Avg Shares Out | 2,309 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 2,309 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$6 | -$10 | -$11 | -$8 |
| % Margin | -996.2% | -1,314.4% | -405.8% | -348.7% |